Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

A0362

Sigma-Aldrich

Adjuplex™ Vaccine Adjuvant

Concentrate, sterile

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

UNSPSC-Code:
12352200
NACRES:
NA.25

Sterilität

sterile

Qualität

NOT FOR HUMAN USE

Versandbedingung

wet ice

Lagertemp.

2-8°C

Allgemeine Beschreibung

Adjuplex potentiates immune responses to vaccines without reactogenicity and has demonstrated superiority to alum, Freund′s adjuvant, Ribi-R730 and numerous other experimental adjuvants. In laboratory animals, Adjuplex has been shown to improve the protective immune response to a variety of experimental human vaccines including HIV, influenza, rotavirus and malaria.

Anwendung

Adjuplex is suitable for use with all types of antigens such as whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP. It is suitable for all routes of administration including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.
Adjuplex™ Vaccine Adjuvant has been used to study the effects of adjuvants for DNA vaccination.

Sonstige Hinweise

Adjuplex Vaccine Adjuvant is a non-denaturing adjuvant that does not contain oils, detergents, preservatives, or components of animal or bacterial origin. Adjuplex is is non-immunogenic and free of allergens, enzymes, mercury, aluminum, and other metals.

Menge

One ml of Adjuplex is sufficient to formulate ten 0.5 ml doses of vaccine.

Rechtliche Hinweise

Adjuplex is a trademark of Advanced BioAdjuvants, LLC

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H319

Gefahreneinstufungen

Eye Irrit. 2

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
SLBS7160
SLBR0940V
SLBP5255V
SLBN2346V
SLBM1261V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  4. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  5. What is used to solubilize Adjuplex ™ Vaccine Adjuvant reagent, Product A0362? 

    The Adjuplex™ Vaccine Adjuvant reagent (Product No. A0362) can be solubilized in a sterile diluent such as phosphate buffered saline (PBS).  Endotoxin-free Dulbecco’s PBS without Ca2+ and Mg2+ is recommended, while unbuffered normal saline is NOT recommended.

  6. What are the adjuvant components of the Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    The formulation of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) is proprietary.  The formulation does not contain any components of animal-origin, microbial origin, or from recombinant technology.

  7. What is the recommended volume dose used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    In general, the dosage volume of Adjuplex™ Vaccine Adjuvant (Product A0362) combined with antigen should be comparable to the dosage volumes used for other adjuvants.  Typical volumes are 0.1-0.2 mL for mice, 0.5 mL for rats and guinea pigs, and 1 mL for rabbits and goats, but these volumes are guidelines only.   For best effect, a dose response curve should be prepared.  

  8. What methods of administration are recommended for antigen preparations using Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) has been found to be suitable for all routes of administration, including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.  

  9. What types of antigen may be used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) is suitable for use with all types of antigens including whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP antigens.  

  10. Can prepared solutions of antigen and Adjuplex™ Vaccine Adjuvant reagent, Product A0362, be stored and reused?

    We do not recommend reusing diluted solutions of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) due to risk of contamination.  We recommend preparing fresh dilutions of Adjuplex™ Vaccine Adjuvant reagent with antigen each time prior to use.

  11. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Production of EV71 vaccine candidates.
Chong P, Hsieh SY, Liu CC, et al.
Human Vaccines & Immunotherapeutics, 8 (2012)
Jane E Libbey et al.
Vaccine, 29(17), 3356-3362 (2010-09-21)
Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for
Cornelis J M Melief
Journal of immunotherapy (Hagerstown, Md. : 1997), 35(3), 215-216 (2012-03-17)
Here, we review a novel vaccine modality, characterized by the administration of long (23 to 45 amino acids) synthetic peptides in incomplete Freund's adjuvant (mineral oil based, Montanide ISA-51), delivered subcutaneously. Such vaccines were first demonstrated to be much more
Rui Kong et al.
Cell, 178(3), 567-584 (2019-07-28)
The vaccine-mediated elicitation of antibodies (Abs) capable of neutralizing diverse HIV-1 strains has been a long-standing goal. To understand how broadly neutralizing antibodies (bNAbs) can be elicited, we identified, characterized, and tracked five neutralizing Ab lineages targeting the HIV-1-fusion peptide
Samantha Burton et al.
Journal of virology, 93(7) (2019-01-18)
The goals of preclinical HIV vaccine studies in nonhuman primates are to develop and test different approaches for their ability to generate protective immunity. Here, we compared the impact of 7 different vaccine modalities, all expressing the HIV-1 1086.C clade
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.